We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.57B
AUM Growth
-$21.5M
Cap. Flow
+$32.3M
Cap. Flow %
1.25%
Top 10 Hldgs %
39.02%
Holding
197
New
37
Increased
49
Reduced
41
Closed
10

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$39M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.2M
3
ESPR
Esperion Therapeutics
ESPR
+$13.9M
4
ABBV icon
AbbVie
ABBV
+$11.5M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$36.3M
2
AMGN icon
Amgen
AMGN
+$29.7M
3
BIIB icon
Biogen
BIIB
+$20.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$19.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.47%
2 Real Estate 2.71%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKBA icon
151
Akebia Therapeutics
AKBA
$362M
$1.27M 0.05%
+132,849
New +$1.86M
HR icon
152
Healthcare Realty
HR
$7.46B
$1.22M 0.05%
46,000
– –
NVAX icon
153
Novavax
NVAX
$1.22B
$1.2M 0.05%
28,550
– –
WELL icon
154
Welltower
WELL
$170B
$1.17M 0.05%
21,400
– –
DOC icon
155
Healthpeak Properties
DOC
$15.2B
$1.06M 0.04%
45,500
– –
CYTK icon
156
Cytokinetics
CYTK
$10.9B
$992K 0.04%
137,797
-212,503
-61% -$1.82M
NTRA icon
157
Natera
NTRA
$38.6B
$962K 0.04%
103,731
-382,027
-79% -$3.75M
MNK
158
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$896K 0.03%
61,900
– –
CYH icon
159
Community Health Systems
CYH
$391M
$808K 0.03%
203,935
– –
HOLX
160
DELISTED
Hologic
HOLX
$730K 0.03%
+19,546
New +$790K
ARNA
161
DELISTED
Arena Pharmaceuticals Inc
ARNA
$665K 0.03%
+16,827
New +$655K
PTCT icon
162
PTC Therapeutics
PTCT
$6.26B
$658K 0.03%
+24,299
New +$616K
CDTX
163
DELISTED
Cidara Therapeutics
CDTX
$635K 0.02%
7,939
-6,385
-45% -$872K
TFX icon
164
Teleflex
TFX
$5.86B
$633K 0.02%
+2,482
New +$652K
VAR
165
DELISTED
Varian Medical Systems, Inc.
VAR
$621K 0.02%
+5,065
New +$604K
XNCR icon
166
Xencor
XNCR
$1.59B
$600K 0.02%
20,000
– –
NSTG
167
DELISTED
NanoString Technologies, Inc.
NSTG
$558K 0.02%
74,250
– –
RMR icon
168
The RMR Group
RMR
$333M
$520K 0.02%
7,441
– –
XRN
169
Chiron Real Estate Inc
XRN
$516M
$510K 0.02%
14,680
– –
FMI
170
DELISTED
Foundation Medicine, Inc.
FMI
$500K 0.02%
+6,353
New +$469K
NCNA
171
NuCana
NCNA
$5.24M
$464K 0.02%
+5
New +$475K
EIGR
172
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$452K 0.02%
+1,528
New +$451K
MTEM
173
DELISTED
Molecular Templates, Inc.
MTEM
$423K 0.02%
+3,526
New +$531K
ASND icon
174
Ascendis Pharma A/S
ASND
$16.5B
$406K 0.02%
+6,214
New +$349K
ORKA
175
Oruka Therapeutics
ORKA
$5.9B
$405K 0.02%
3,756
– –
4 5 6
7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Tekla Capital Management held 197 positions worth $2.57B, down 0.83% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q1 2018 filing shows 37 new, 49 increased, 41 reduced and 10 closed positions. Its largest new stake was Esperion Therapeutics: 189,287 shares worth $13.7M. The largest sale was Gilead Sciences, an estimated $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q1 2018 buy was Esperion Therapeutics: 189,287 shares worth $13.7M.
  • Tekla Capital Management added most to Pfizer in Q1 2018, an estimated $39M increase.
  • Tekla Capital Management's biggest Q1 2018 reduction was Gilead Sciences, cutting an estimated $36.3M.
  • Tekla Capital Management fully exited NuVasive, Inc. in Q1 2018, selling an estimated $6.87M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.57B portfolio in Q1 2018.
  • Tekla Capital Management opened 37 new positions and closed 10 in Q1 2018.
  • Tekla Capital Management's portfolio value fell 0.83% quarter-over-quarter to $2.57B.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.